They'd better have the G4 ready for delivery to customers at the ASHP show otherwise they're going to have canceled contracts and no one will take them seriously anymore- not that they do now.
Like the other Valimeds, no one is going to buy these things, they'll be pay-per-use transactions except without the on going cuvette sales.
Still a highly niche market for compounded, high-risk, liquid meds.
Nothing much has changed except that they won't be selling cuvettes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.